S&CO Inc. Sells 2,358 Shares of Johnson & Johnson $JNJ

S&CO Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 163,723 shares of the company’s stock after selling 2,358 shares during the quarter. Johnson & Johnson accounts for 1.6% of S&CO Inc.’s holdings, making the stock its 16th biggest holding. S&CO Inc.’s holdings in Johnson & Johnson were worth $25,008,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson in the first quarter worth approximately $218,000. Smart Money Group LLC boosted its holdings in Johnson & Johnson by 6.5% in the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after acquiring an additional 407 shares during the last quarter. Diversify Wealth Management LLC boosted its holdings in Johnson & Johnson by 16.8% in the first quarter. Diversify Wealth Management LLC now owns 23,008 shares of the company’s stock valued at $3,587,000 after acquiring an additional 3,317 shares during the last quarter. Finally, Gateway Wealth Partners LLC increased its position in Johnson & Johnson by 17.4% during the 1st quarter. Gateway Wealth Partners LLC now owns 2,729 shares of the company’s stock valued at $453,000 after purchasing an additional 404 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on JNJ shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a research report on Monday, October 20th. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, HSBC upped their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Stock Down 0.3%

Shares of NYSE:JNJ opened at $186.50 on Monday. The business’s 50 day moving average is $184.25 and its 200 day moving average is $168.80. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The stock has a market cap of $449.34 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.19 and a beta of 0.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s payout ratio is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.